Boulder, CO 9/5/18—Inscripta, a supplier of gene editing tools for researchers, has acquired Solana Biosciences. Financial details were not provided. “Inscripta is building the tools to take on the next frontier of gene editing discoveries,” said Inscripta CEO Kevin Ness. “The addition of the Solana team brings world-class scientific product development, manufacturing and operations experience to further enable Inscripta to provide the best gene editing tools to both commercial and academic researchers.” Tom Russo, one of Solana Biosciences’ founders and former vice president of Operations at Illumina, will become vice president of Operations for Inscripta.

Last year, Inscripta released its first products, CRISPR enzymes, announcing that they are available with no up-front licensing fees or so-called “reach-through royalties,” which require royalties on products resulting from the use of the technology. In addition to enzymes, the company plans to commercialize software, instruments and reagents.